Eldecalcitol

Eldecalcitol has been studied in 20 papers since 2017: 5 trials and 3 observational studies in people, 8 in animals, 4 reviews; 10 in the past year. The newest paper, Oct 21, 2026: “Clinical investigation of effects of eldecalcitol on lipid profile and other metabolic parameters in osteoporosis-treatment-naïve postmenopausal women with osteoporosis”.

Intervention

20 papers study it5 more mention it35 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 25 papers on eldecalcitol

At a glance

The findings reach people, from one lab or study. 8 independent labs in 2 countries; 6 trials, 1 about aging, 2 with no results posted.

“3-year BMD increases were progressively greater with more favorable glycemic trajectories”
Metabolic status modifies skeletal response to active vitamin D: A post hoc analysis of the DPVD randomized trialThe Journal of clinical endocrinology and metabolism2026doi:10.1210/clinem/dgag396

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 8 independent labs in 2 countries
  • 6 trials, 1 about aging, 2 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 3 of 34 findings with company ties
  • 1 of 6 trials sponsored by its developers
  • Human trial5
  • Humans3
  • Animals8

Studies in people

5 studies gave eldecalcitol to people and measured what changed.

What changedDesignPeopleSource

up: Increases bone mineral density T-score

Trial24 weeks54 peopleWomenPostmenopausal women; osteoporosis-treatment-naïve postmenopausal women with osteoporosisDrug discoveries & therapeutics, Oct 21, 2026

up: Improves lumbar spine bone mineral density4.6% in progression, 7.3% in persistent, 9.2% in regression

Treated cohort3 years1,164 peopleIn participants with prediabetes receiving eldecalcitolThe Journal of clinical endocrinology and metabolism, Sep 29, 2026

up: Increases skeletal muscle mass1.9 % vs. -3.4 % change, eldecalcitol vs placebo

up: Increases muscle strength4.1 % vs. -0.7 % change, eldecalcitol vs placebo

down: Decreases fat mass-3.2 % vs. 1.8 % change, eldecalcitol vs placebo

Randomized trial1 year32 peopleMetabolism: clinical and experimental, Mar 28, 2025

down: Lowers the risk of sarcopeniaHR 0.51, 95% CI 0.31 to 0.83

no change: Has no effect on adverse events

Randomized trialmedian 2·9 years1,094 peopleBothmean age 60·8 yearsOlder adults; prediabetesThe lancet. Healthy longevity, Mar 1, 2024

up: Increases quadriceps muscle strength

no change: Has no effect on balance and walking abilities

no change: Has no effect on falls

Randomized trial6 months226 peopleWomenpostmenopausalPostmenopausal women; postmenopausal women with osteoporosisJournal of orthopaedic science : official journal of the Japanese Orthopaedic Association, Mar 3, 2020

What did studies of eldecalcitol find?

30

Studies of eldecalcitol measured 30 outcomes; the most studied are cellular senescence (4 studies) and bone loss (2).

Cellular senescence

downin rat cells2downin cells1downin mouse cells1

4 studies
  1. Eldecalcitol inhibits cellular senescence in dexamethasone-treated type H vascular endothelial cells.

    “inhibiting vascular endothelial cells (ECs) senescence and improving angiogenesis and osteogenesis.”

    Cellsin dexamethasone-treated type H vascular endothelial cells

    ED-71 prevents glucocorticoid-induced bone loss by inhibiting type H vascular endothelial cell senescence through maintaining mitochondria-associated membrane-mediated calcium homeostasis

    Cellular signalling

  2. Eldecalcitol inhibits cellular senescence in H2O2-treated macrophages.

    “ED-71 effectively reduced cellular senescence-related indicators such as p16, p53 and β-galactosidase in macrophages”

    Cellsin H2O2-treated macrophages

    ED-71 alleviates OVX-induced osteoporosis by inhibiting macrophage senescence through SIRT1/PGC-1α pathway: A potential therapeutic approach

    Bone

  3. Eldecalcitol decreases cellular senescence in H2O2-treated osteoblasts.

    “The combined effects of these two factors synergistically contribute to the improvement in osteoblast senescence.”

    Cellsin H2O2-treated osteoblasts

    ED-71 ameliorates OVX-induced osteoporosis by regulating calcium homeostasis and SIRT1-mediated mitochondrial function, alleviating osteoblast senescence and suppressing osteoclastogenesis

    Cellular signalling

  4. Eldecalcitol decreases cellular senescence in bone mesenchymal stem cells from ovariectomized rats.

    “ED-71 significantly improved the bone mesenchymal stem cells senescence caused by ovariectomized.”

    Cellsin bone mesenchymal stem cells from ovariectomized ratsbone mesenchymal stem cell

    Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal

    Frontiers in pharmacology

More on Cellular senescence

Bone loss

downin animals1downin rats1

2 studies
  1. Eldecalcitol prevents bone loss in dexamethasone-induced osteoporosis.

    “ED-71 prevents glucocorticoid-induced bone loss”

    Animalsin dexamethasone-induced osteoporosis

    ED-71 prevents glucocorticoid-induced bone loss by inhibiting type H vascular endothelial cell senescence through maintaining mitochondria-associated membrane-mediated calcium homeostasis

    Cellular signalling

  2. Eldecalcitol prevents bone loss in ovariectomized rats.

    “ED-71 prevented bone loss and inhibited weight gain in ovariectomized rats.”

    Animalsin ovariectomized ratsbone30 ng/kg

    Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal

    Frontiers in pharmacology

Bone mineral density T-score

upin humans1

1 study
  1. Eldecalcitol increases bone mineral density T-score in humans (osteoporosis-treatment-naïve postmenopausal women with osteoporosis).

    “T-scores (lumbar spine and femoral neck) significantly improved from baseline to 24 weeks after eldecalcitol administration (each P < 0.001).”

    Human trialosteoporosis-treatment-naïve postmenopausal women with osteoporosislumbar spine and femoral neck0.75 μg per day24 weeksfemalesn = 54

    Clinical investigation of effects of eldecalcitol on lipid profile and other metabolic parameters in osteoporosis-treatment-naïve postmenopausal women with osteoporosis

    Drug discoveries & therapeutics

More on Bone mineral density T-score

Lumbar spine bone mineral density

upin humans1

1 study
  1. Eldecalcitol improves lumbar spine bone mineral density in participants with prediabetes receiving eldecalcitol (4.6% in progression, 7.3% in persistent, 9.2% in regression).

    “3-year BMD increases were progressively greater with more favorable glycemic trajectories”

    Human trialin participants with prediabetes receiving eldecalcitol3 years

    Metabolic status modifies skeletal response to active vitamin D: A post hoc analysis of the DPVD randomized trial

    The Journal of clinical endocrinology and metabolism

Femoral neck bone mineral density

upin humans1

1 study
  1. Eldecalcitol is linked with higher femoral neck bone mineral density in humans.

    “eldecalcitol co-therapy was independently associated with femoral neck BMD response”

    Humans1 yearfemales

    Site-Specific Responses to SERM Treatment in Postmenopausal Osteoporosis: No Clear Age Attenuation in a Real-World Study

    Medicina (Kaunas, Lithuania)

More on Femoral neck bone mineral density

Postmenopausal osteoporosis

downin rats1

1 study
  1. Eldecalcitol protects against postmenopausal osteoporosis in ovariectomized rats.

    “Potential modulation of ED-71 in regulating H3K18 histone lactylation to suppress osteoclast differentiation and alleviate postmenopausal osteoporosis”

    Animalsin ovariectomized rats

    Potential modulation of ED-71 in regulating H3K18 histone lactylation to suppress osteoclast differentiation and alleviate postmenopausal osteoporosis

    Biochemical pharmacology

More on Postmenopausal osteoporosis

Osteoclast differentiation

downin rats1

1 study
  1. Eldecalcitol inhibits osteoclast differentiation in ovariectomized rats and in vitro osteoclasts.

    “ED-71 treatment effectively disrupts this regulatory axis by suppressing glycolysis, reducing H3K18la levels, and alleviating ER stress, inhibiting SOCE and restoring bone homeostasis.”

    Animalsin ovariectomized rats and in vitro osteoclasts

    Potential modulation of ED-71 in regulating H3K18 histone lactylation to suppress osteoclast differentiation and alleviate postmenopausal osteoporosis

    Biochemical pharmacology

Mitochondrial calcium overload

downin cells1

1 study
  1. Eldecalcitol decreases mitochondrial calcium overload in dexamethasone-treated cells.

    “reduces MAM-mediated mitochondrial calcium overload, inhibits senescence of ECs”

    Cellsin dexamethasone-treated cells

    ED-71 prevents glucocorticoid-induced bone loss by inhibiting type H vascular endothelial cell senescence through maintaining mitochondria-associated membrane-mediated calcium homeostasis

    Cellular signalling

Bone mass

upin mice1

1 study
  1. Eldecalcitol improves bone mass in OVX mice.

    “ED-71 improved bone mass and aging in OVX mice”

    Animalsin OVX mice

    ED-71 alleviates OVX-induced osteoporosis by inhibiting macrophage senescence through SIRT1/PGC-1α pathway: A potential therapeutic approach

    Bone

Osteogenic differentiation

upin mouse cells1

1 study
  1. Eldecalcitol improves osteogenic differentiation in indirect co-culture system with senescent macrophages.

    “senescent macrophages impaired BMSCs osteogenic differentiation, an effect reversed by ED-71”

    Cellsin indirect co-culture system with senescent macrophages

    ED-71 alleviates OVX-induced osteoporosis by inhibiting macrophage senescence through SIRT1/PGC-1α pathway: A potential therapeutic approach

    Bone

FOXO1 signaling

upin humans1

1 study
  1. Eldecalcitol increases FOXO1 signaling in humans (versus placebo).

    “eldecalcitol treatment for 1 year resulted in higher phosphorylation levels of mTOR and FOXO1 signaling pathways”

    Human trialversus placeboskeletal muscle1 year

    Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial

    Metabolism: clinical and experimental

mTOR signaling

upin humans1

1 study
  1. Eldecalcitol activates mTOR signaling in humans (versus placebo).

    “eldecalcitol treatment for 1 year resulted in higher phosphorylation levels of mTOR and FOXO1 signaling pathways”

    Human trialversus placeboskeletal muscle1 year

    Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial

    Metabolism: clinical and experimental

More on mTOR signaling

Fat mass

downin humans1

1 study
  1. Eldecalcitol decreases fat mass in humans (versus placebo) (-3.2 % vs. 1.8 % change, eldecalcitol vs placebo).

    “and lower fat mass (-3.2 % vs. 1.8 %, p = 1.73E-12)”

    Human trialversus placebo1 yearn = 32

    Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial

    Metabolism: clinical and experimental

Muscle strength

upin humans1

1 study
  1. Eldecalcitol increases muscle strength in humans (versus placebo) (4.1 % vs. -0.7 % change, eldecalcitol vs placebo).

    “and muscle strength (4.1 % vs. -0.7 %, p = 2.57E-17)”

    Human trialversus placebo1 yearn = 32

    Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial

    Metabolism: clinical and experimental

Skeletal muscle mass

upin humans1

1 study
  1. Eldecalcitol increases skeletal muscle mass in humans (versus placebo) (1.9 % vs. -3.4 % change, eldecalcitol vs placebo).

    “the eldecalcitol group had significantly higher skeletal muscle mass (1.9 % vs. -3.4 %, p = 3.26E-9)”

    Human trialversus placeboskeletal muscle1 yearn = 32

    Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial

    Metabolism: clinical and experimental

All 30

What is eldecalcitol linked with?

1

Studies link eldecalcitol with sarcopenia.

Sarcopenia

downin humans1HR 0.51

1 study
  1. Eldecalcitol lowers the risk of sarcopenia in humans (prediabetes) (HR 0.51, 95% CI 0.31 to 0.83).

    “Eldecalcitol treatment as compared with placebo showed statistically significant preventive effect on sarcopenia incidence”

    Human trialprediabetes0·75 μg per daymedian 2·9 yearsn = 1,094

    Active vitamin D treatment in the prevention of sarcopenia in adults with prediabetes (DPVD ancillary study): a randomised controlled trial

    The lancet. Healthy longevity

More on Sarcopenia

Has eldecalcitol been tested in people?

1 of 6 about aging

Yes: 5 trials and 3 observational studies in people have been published, and 5 trials are registered.

About aging

Every condition in trials

Trial sponsors

Latest

Dec 2025: 2Jan 2026: 0Feb 2026: 1Mar 2026: 1Apr 2026: 1May 2026: 1Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 1Nov 2026: 09 papers in 12 months

See all 25 papers on eldecalcitol